| Bioactivity | ERDRP-0519, an orally bioavailable small-molecule Measles virus (MeV) polymerase inhibitor, prevents measles disease in squirrel monkeys (Saimiri sciureus). ERDRP-0519 inhibits morbilliviruses with nanomolar potency.[1][2][3]. | ||||||||||||
| Invitro | ERDRP-0519 exhibits potency against a panel of Measles virus (MeV) isolates with EC50s of 0.07- 0.3 µM[1]. ERDRP-0519 exhibits potency against MeV and related pathogens of the Morbillivirus genus, such as canine distemper virus (CDV)[3]. | ||||||||||||
| In Vivo | A single-dose pharmacokinetic (PK) study is performed in squirrel monkeys by oral (intragastric) delivery of ERDRP-0519 (50 mg/kg) and blood sampling at seven predefined time points after dosing. Serum concentrations peak ~2 h post-administration (Cmax=3.27 µM)[3]. | ||||||||||||
| Name | ERDRP-0519 | ||||||||||||
| CAS | 1374006-96-8 | ||||||||||||
| Formula | C23H30F3N5O4S | ||||||||||||
| Molar Mass | 529.58 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Stefanie A Krumm, et al. An orally available, small-molecule polymerase inhibitor shows efficacy against a lethal morbillivirus infection in a large animal model. Sci Transl Med. 2014 Apr 16;6(232):232ra52. [2]. Richard K Plemper. Measles Resurgence and Drug Development. Curr Opin Virol. 2020 Apr;41:8-17. [3]. Kevin Wittwer, et al. Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nat Commun. 2021 Sep 2;12(1):5233. |
ERDRP-0519
CAS: 1374006-96-8 F: C23H30F3N5O4S W: 529.58
ERDRP-0519, an orally bioavailable small-molecule Measles virus (MeV) polymerase inhibitor, prevents measles disease in
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.